Jun. 18 at 3:39 PM
$PACB Oh look, Nanopore still has fundamental, physically entrenched accuracy issues (they were a fraud and we always knew it)
In Pilot Study, Oxford Nanopore Shows Promise for Rare Disease Testing but Misses Some CNVs : GOTHENBURG, Sweden – Researchers at University Medical Center Utrecht in the Netherlands have found that Oxford Nanopore's sequencing technology is promising for rare genetic disease testing, but still needs to improve its ability to correctly call diagnostically relevant copy number variants, along with better data visualization and quality control tools.
$TXG 10x is rock solid tech and has a great future but it is apples to oranges with
$PACB which will also run soon, once we shake off a few crusty short seller 'tards
